PMID- 15344542
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20201208
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 62
IP  - 8
DP  - 2004 Aug
TI  - [Pathogenesis and treatment of refractory gastroesophageal reflux disease in 
      Japanese patients].
PG  - 1510-5
AB  - Prevalence of refractory gastroesophageal reflux disease (GERD) defined as a 
      patient who have persistent GERD symptoms during treatment with proton pump 
      inhibitor (PPI) is rare in Japanese patinets. Pathogenesis of refractory GERD is 
      associated with several factors including dysfunction of esophageal motility, 
      presence of severe hiatal hernia, complication such as stricture and short 
      esophagus, extensive metabolizer of CYP2C19 genotype, nocturnal gastric acid 
      breakthrough, absence of H. pylori infection, or bile reflux. Examination by 24 
      hr pH monitoring is necessary to assess refractory GERD and if acid suppression 
      is insufficient, treatment with double doses of PPIs or combination of PPI and H2 
      blocker is effective. However, most cases of refractory GERD are required 
      surgical treatment. Endoscopic therapy might be useful for refractory GERD in 
      future.
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
AD  - Department of Gastroenterology, Osaka City University, Graduate School of 
      Medicine.
FAU - Higuchi, Kazuhide
AU  - Higuchi K
FAU - Yamamori, Kazuki
AU  - Yamamori K
FAU - Watanabe, Yoko
AU  - Watanabe Y
FAU - Shiba, Masatsugu
AU  - Shiba M
FAU - Watanabe, Toshio
AU  - Watanabe T
FAU - Tominaga, Kazunari
AU  - Tominaga K
FAU - Oshitani, Nobuhide
AU  - Oshitani N
FAU - Matsumoto, Takayuki
AU  - Matsumoto T
FAU - Arakawa, Tetsuo
AU  - Arakawa T
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
SB  - IM
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Cytochrome P-450 CYP2C19
MH  - Enzyme Inhibitors/administration & dosage
MH  - Esophageal Motility Disorders/complications
MH  - Esophageal Stenosis/complications
MH  - Esophagoscopy
MH  - Esophagus/physiopathology
MH  - Gastric Acid/metabolism
MH  - Gastroesophageal Reflux/diagnosis/*etiology/*therapy
MH  - Genotype
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Hernia, Hiatal/complications
MH  - Histamine H2 Antagonists/administration & dosage
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Japan
MH  - Life Style
MH  - Mixed Function Oxygenases/genetics
MH  - Monitoring, Physiologic
MH  - Proton Pump Inhibitors
RF  - 15
EDAT- 2004/09/04 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2004 Aug;62(8):1510-5.